GLP-1 Drugs and Headache: A Side Effect, and a Treatment

These drugs cause headaches and are being studied as a treatment for one. The Wegovy label reports headache in 14% of patients against 10% on placebo.^[4] Meanwhile a randomized trial using pressure monitors implanted in the skull found a GLP-1 measurably lowered intracranial pressure in women with idiopathic intracranial hypertension — a condition whose defining symptom is headache.^[1] A 2025 review titles this problem exactly: when these medications are therapeutic, and when they contribute to the symptom.^[2]

The side effect, first

Headache sits in the adverse reactions table of the label, not in a warning section, which places it among the common and generally self-limiting effects rather than the dangerous ones. In the adult weight-management trials it was reported by 14% of people on Wegovy and 10% on placebo.^[4] That gap is real and it is narrow: most headaches in that trial happened to people who were not on the drug.

Dehydration is the mechanism worth knowing about, because it is the one you can do something about. Nausea, vomiting and reduced fluid intake all follow from how these drugs work, and all of them cause headaches independently. Our water intake calculator works a target, and how long side effects last covers the early-weeks pattern most of them follow.

The condition where this gets interesting

Idiopathic intracranial hypertension is raised pressure around the brain with no tumor or clot to explain it. It causes severe headache and, because the pressure is transmitted to the optic nerve, it can take your sight. It is strongly associated with obesity, and it predominantly affects women of childbearing age — which is to say, a population heavily overlapping the one being prescribed these drugs for weight.

Weight loss has long been the most effective treatment, which made a weight-loss drug an obvious thing to test. What was not obvious is that GLP-1 receptor signaling might lower intracranial pressure directly, which is what the preclinical work suggested.^[1]

What the trial did

The design is the impressive part. Rather than asking participants how their headaches felt, the researchers used telemetric catheters to monitor intracranial pressure continuously, giving an objective endpoint of a kind headache research rarely gets.^[1] Adult women with active disease — pressure above 25 cmCSF and swelling of the optic disc — received exenatide or placebo, double-blind.

Participants averaged 28 years old, a BMI of 38.1, and a starting pressure of 30.6 cmCSF.^[1] A drop of roughly 6 from that baseline is not cosmetic. And it happened within hours, which is faster than any weight change could explain — the strongest argument that something other than weight loss is doing the work.

Migraine is a weaker story, and worth separating

A 2024 systematic review searched the whole GLP-1-and-pain literature, screening 833 records down to 42 studies across inflammatory pain, headache, neuropathic pain and visceral pain.^[3] What it found for headache specifically is mechanistic: GLP-1 appears to be involved in migraine biology, and GLP-1 drugs show analgesic effects in animal models of inflammatory and neuropathic pain.

That is a reason to run trials. It is not a reason to expect your migraines to improve, and the distinction matters because obesity and migraine are themselves linked — people with obesity who have migraine are at higher risk of it becoming chronic, so weight loss by any route may help without the drug doing anything to the migraine directly.^[2]

Strong evidence in one headache disorder is not evidence in headache.

If you get headaches on one of these

• Fluids first. The gastrointestinal effects dehydrate people, dehydration causes headache, and this is the part within your control.
• Tell your prescriber if it is new, severe, or different from your usual pattern. That is the standard advice for headache generally, and it is not weakened by being on a drug that lists headache.
• Vision changes with headache are urgent. Blurring, transient greying-out, or double vision alongside headache is how raised intracranial pressure presents, and it is a same-day problem rather than a wait-and-see one.
• Do not self-treat a headache disorder with a weight-loss drug. No GLP-1 is approved for any headache condition, and the IIH evidence is a 15-person trial.

For the separate question of what these drugs do to the eye, our NAION and retinopathy article covers the vision risks that have their own evidence base.